Novartis Rescula First-Line Indication Would Require Timolol Equivalence
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Companies seeking a first-line indication for glaucoma drugs need to show that their agents have IOP (intraocular pressure) reduction levels equivalent or superior to those of the beta-blocker timolol, FDA said in review documents for Novartis Ophthalmics’ (formerly Ciba Vision’s) Rescula (unoprostone 0.15%).
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class